Vanessa Ferreira Salvador

Vanessa Ferreira Salvador

Auto-generated profile, based on publicly available information

Vanessa Ferreira Salvador

Center for Veterinary Parasitology, School of Veterinary and Animal Science, Federal University of Goiás, Goiânia, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2024 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
DZDina Maria Beltran Zapa
Dina Maria Beltran Zapa
LALidia Mendes de Aquino
Lidia Mendes de Aquino
LCLuiz Felipe Monteiro Couto
Luiz Felipe Monteiro Couto
LHLuciana Maffini Heller
Luciana Maffini Heller
IMIgor Maciel Lopes de Morais
Igor Maciel Lopes de Morais
WLWelber Daniel Zanetti Lopes
Welber Daniel Zanetti Lopes
Background: In 2022, fluralaner was launched on the market for use in the control of the cattle tick Rhipicephalus microplus after showing 100% efficacy in registration trials against the causative agents of cattle tick fever (TFAs). The aim of the present study was to determine whether a strategic control regimen against R. microplus using fluralaner (FLU) in Holstein calves grazing in a tropical region would alter the enzootic stability status of cattle tick fever, triggering outbreaks in these animals up to 22 months age. Methods: In this study, a group of calves treated with FLU was compared with a control group treated with the regimen currently being used on the farm, which consisted of the fipronil + fluazuron formulation (FIFLUA). In the first experiment, the efficacy of the FIFLUA pour-on formulation was evaluated in a field study. In the second experiment, which lasted 550 days, two experimental groups (n = 30/group) of Holstein calves naturally infested with R. microplus were analyzed. Calves aged 4 to 10 months received either a specific treatment regimen with FLU (experimental group) or FIFLUA (control group). During this period, tick counts, animal weight measurement, feces collection (to determine eggs and oocysts per gram of feces), tick fever monitoring, blood smears (to ascertain enzootic stability of the herd), PCR testing for TFAs and serology (indirect enzyme-linked immunosorbent assay [iELISA]) were performed. All calves were evaluated for signs of tick fever between ages 11 and 22 months. Results: FIFLUA showed an acaricidal efficacy of > 90% from post-treatment days 14 to 35. Regarding treatments against the TFAs, the average number of treatments was similar between groups, but animals treated with FLU had a smaller reduction in packed cell volume on some of the evaluation dates of the second and third treatment against TFAs. In calves aged 10 months in the FLU group, B. bovis was not detected by PCR (0/15 samples), 40% of the samples had antibody titers and 33% (10/30) of the samples had positive blood smears. Regarding B. bigemina, > 86% of the samples in both groups tested positive for B. bigemina DNA and antibodies; there was no difference in the antibody titers between the groups. There were no clinical cases of cattle tick fever in calves aged 11 to 22 months. Conclusions: In comparison with the control treatment, the strategic control regimen against R. microplus with FLU that was implemented in the present study did not negatively affect the enzootic stability status of A. marginale and B. bigemina in the herd up to 22 months of age. The enzootic stability status of B. bovis was not reached by either group. These results likely represent a characteristic of the local tick population, so further studies should be performed. Graphical

17 October 2025 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
LALidia Mendes de Aquino
Lidia Mendes de Aquino
IMIgor Maciel Lopes de Morais
Igor Maciel Lopes de Morais
VSVanessa Ferreira Salvador
Vanessa Ferreira Salvador
LLLuccas Lourenzzo Lima Lins Leal
Luccas Lourenzzo Lima Lins Leal
NRNathalia Braz Ribeiro
Nathalia Braz Ribeiro
WLWelber Daniel Zanetti Lopes
Welber Daniel Zanetti Lopes
Background: Little is known about the impact of fluralaner on herd enzootic stability regarding tick fever pathogens (TFPs). This study aimed to assess whether implementing strategic control of Rhipicephalus microplus using fluralaner could influence the enzootic stability of beef herds regarding TFPs on a farm where this compound had never been previously used. Methods: One hundred Bos taurus indicus calves were divided into two groups of 50 animals each. One group underwent strategic tick control with pour-on fluralaner at 2.5 mg/kg (FLU), while the control group received a pour-on combination of fipronil 1.25 mg/kg + fluazuron 2.5 mg/kg (FIFLUA), a protocol used on the farm for 12 years. Calves were monitored from 25 to 241 days of age (weaning). During this period, in addition to acaricide treatments, tick counts and TFP diagnosis via indirect enzyme-linked immunosorbent assay (iELISA), quantitative polymerase chain reaction (qPCR), and blood smears were conducted in both groups. Results: FIFLUA animals received four acaricide treatments at 25, 60, 135, and 188 days of age, with intervals of 35, 75, and 53 days. FLU animals received three acaricide treatments, at 25, 135, and 188 days of age, with intervals of 110 and 53 days. The average tick count in the FLU group was significantly lower than in the FIFLUA group at 60 days (Kruskal–Wallis, H = 97.85, df = 1, P < 0.0001) and 241 days (H = 18.12, df = 1, P < 0.0001). Anaplasma marginale bacteremia was lower in the FLU group at 60 days (H = 3.98, df = 1, P = 0.0459). Serologically, enzootic stability for Babesia bovis was achieved at 135 and 188 days in the FLU and FIFLUA groups, respectively. For B. bigemina, over 75% of calves in both groups showed antibodies at 60 and 188 days, respectively. For A. marginale, enzootic stability was reached at 188 days (FLU) and 241 days (FIFLUA). Conclusions: Strategic tick control with fluralaner did not compromise the development of enzootic stability to B. bovis, B. bigemina, and A. marginale. Over 75% of FLU-treated calves showed seroconversion at 133, 60, and 188 days, respectively. Graphical